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ABSTRACT
A novel series of thiosemicarbazone-triazole hybrids were efficiently synthesized and evaluated for their activity against the 3D7
strain of the malaria parasite, Plasmodium falciparum. Although the hybrids were found not to be as potent as the standard
chloroquine, they have shown activities interesting enough to warrant future structure activity relationship (SAR) studies.
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1. Introduction
Malaria is an infectious disease claiming the lives of millions of
people in the developing countries. According to the recent
World Health Organization (WHO) report there are between
300 million and 500 million cases of malaria worldwide annually
and more than 1 million people die from the disease, most of
them children under the age of five years.1 Ninety per cent of the
cases and 75 % of the deaths occur in sub-Saharan Africa.1
Chloroquine, a 4-aminoquinoline, has been the most reliable
and effective drug for the treatment of malaria for much of the
past five decades. Even though the drug has several advantages
including limited host toxicity, low cost and effective and well-
established synthesis protocols, its use has been hampered by
the emergence of chloroquine-resistant strains of malaria.2,3
Currently, artemisinin-based combination therapy (ACT) is
WHO’s standard treatment against Plasmodium falciparum
malaria, the most lethal species that cause malaria in humans, in
which the regimen uses a double or triple combination therapy
with the aim of either delaying or preventing the development
of drug resistance.4–6 Although no clinical resistance has been
registered against artemisinins, recent reports from South-East
Asia are increasingly pointing to tolerance, which may eventu-
ally lead to resistance against this class of drugs.7 The wide-
spread emergence of drug-resistant strains calls for the search
for new drugs preferably with novel mechanisms of action.8 One
approach in tackling some of the problems has been via the use
of the so-called hybrid drugs, which comprise two or more drug
pharmacophores in one molecule with the intention to exert
multi-drug action.9 For instance, trioxaquines are synthetic
hybrid molecules containing two covalently linked pharma-
cophores (1,2,4-trioxane and an aminoquinoline), a concept
referred to as ‘covalent biotherapy’, and thus possesses a dual
mode of action, namely heme alkylation with the trioxane entity,
and heme stacking and inhibition of haemozoin formation with
the aminoquinoline moiety.10,11 The trioxaquines exhibited
improved antimalarial activity over their individual fragments,
indicating a potentially synergistic effect of the hybrids.10 In the
pursuit of novel hybrid drugs against malaria, we are interested
in the synthesis of thiosemicarbazone and triazole hybrid
compounds which to the best of our knowledge have not been
reported in the literature. Thiosemicarbazones, having several
metal binding sites, possess a wide spectrum of biological activity
which includes antiviral,12 anticancer13 and antimalarial14 activities
probably mediated via chelation to intracellular cations. Equally
important are triazoles which can interact with biological targets
through hydrogen bonding and dipole interactions.15 They are
the main structural features of a number of antifungal drugs
(e.g. fluconazole, isavuconazole, itraconazole, variconazole,
pramiconazole, ravuconazole and posaconazole).16 Besides their
potent antifungal activities, they also exhibit analgesic,
anti-inflammatory, local anaesthetic, anticonvulsant, antineo-
plastic, antiviral and antimalarial activities.17–19
These clinically important activities of thiosemicarbazone and
triazole moieties prompted us to investigate the antimalarial
activity of the hybrid structure of the two. Herein, we report the
synthesis of such novel hybrids 1a–i (Fig. 1) having various
R groups and their activity against P. falciparum.
RESEARCH ARTICLE H.H. Kinfe and Y.H. Belay, 130
S. Afr. J. Chem., 2013, 66, 130–135,
<http://journals.sabinet.co.za/sajchem/>.
*To whom correspondence should be addressed. E-mail: hhkinfe@uj.ac.za
Figure 1 General chemical structure of the proposed thiosemicarba-
zone-triazole hybrids.
2. Results and Discussion
2.1 Synthesis
The synthesis of the target hybrid structure is outlined in
Scheme 1. The synthesis commenced with alkylation of commer-
cially available 4-hydroxybenzaldehyde with propargyl bromide
in the presence of K2CO3 to give 3 which incorporates an alkynyl
group required for click chemistry.20 Compound 3 was then
subjected to click chemistry with freshly prepared benzyl azide
to provide 1,4-disubstituted triazole 4.21 The structure of the
triazole was established using 1H NMR spectroscopy. Disappear-
ance of the signal for the terminal alkyne proton at 2.54 ppm and
appearance of the characteristic signal for the alkene proton of
the triazole ring at 7.53 ppm were evidence in support of the
structure. X-ray crystallographic analysis further confirmed that
the triazole formed was the 1,4-disubstituted isomer as shown in
Fig. 2 (see experimental section for deposition details).
Methylhydrazinecarbodithioate 6, which was prepared in a one
pot synthesis from the condensation of hydrazine monohydrate,
CS2 and methyl iodide,
22 was reacted with triazole 4 under
Schiff ’s base condensation reaction conditions to give com-
pound 7.22 The structure of the compound was established using
NMR spectroscopy. Disappearance of the signal due to the alde-
hydic proton at 9.85 ppm and carbonyl carbon signal at
190.8 ppm from triazole 4, and appearance of a methyl signal at
2.50 ppm and C=S signal at 197.6 ppm in the 1H and 13C NMR
spectra, respectively, confirmed formation of compound 7. The
latter then underwent nucleophilic substitution reactions with a
series of primary amines to provide a library of hybrid com-
pounds 1a–i as shown in Table 1.
2.2. In vitro Antiplasmodial Activity
The synthesized hybrid compounds were evaluated for their
in vitro antiplasmodial activity against 3D7 strain of the malaria
parasite, P. falciparum, using chloroquine as a reference drug.
The percentage parasite viability results after exposure of the
P. falciparum to the synthesized hybrid compounds is summa-
rized in Fig. 3 and Table 2. Unfortunately, out of all the compounds
tested, only compound 1f exhibited less than 50 % parasite
viability (46 % compared to 38 % of chloroquine). The remaining
compounds displayed more than 50 % parasite viability with 1a
showing no activity at all. Compounds with longer aliphatic
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Scheme 1
(i) K2CO3, propargyl bromide, acetone, reflux, 2.5 h, 92 %; (ii) BnN3, CuSO4.5H2O, sodium ascorbate, DMF:H2O (4:1), 60 °C, 3 h, 80 %; (iii) CS2,
KOH, CH3I, H2O:isopropanol (1:1), rt, 4 h, 90 %; (iv) 4, 6, MeOH, reflux, overnight, 89 %; (v) RNH2, MeOH, reflux, 24 h, 62–85 %.
Figure 2 Crystal structure of triazole 4.
Figure 3 pLDH assay of thiosemicarbazone-triazole 1a–i at 10 µg/mL
and of the standard chloroquine at 1 µg/mL incubated for 48 h.
chains such as 1b, 1c and 1d exhibited lower percentage parasite
viability (56, 61 and 61 %, respectively) when compared to
compounds with shorter alkyl chains such as 1a and 1e which
exhibited 68 and 100 %, respectively. Similar results were also
obtained with the aryl amine groups where extension of the
carbon chain in 1g by one to 1h resulted in almost 20 % decrease
in parasite viability.
3. Conclusion
Novel thiosemicarbazone-triazole hybrids were successfully
synthesized and evaluated for their antiplasmodial activity.
While the compounds turned out not to be very potent, they
showed interesting activity, thus warranting further investiga-
tion. We are currently trying to improve activity by synthesising
analogues of 1f, which is the most active hybrid in the series and
our results will be reported in due course.
4. Experimental
All the solvents used were AR grade and all the reagents were
purchased from Sigma Aldrich. The reactions were monitored
by thin layer chromatography (TLC) on aluminium-backed
Merck silica gel 60 F254 plates using an ascending technique when
required. The plates were visualized under UV light. Gravity
column chromatography was done on Merck silica gel 60
(70–230 mesh). Melting points were determined using a
Reichert-Jung Thermovar hot-stage microscope and are uncor-
rected. Infrared spectra were recorded using Tensor 27 Brucker
and Perkin Elmer FT-IR spectrum BX. Elemental analyses were
performed on a Vario Elementar III microcube CHNS analyzer at
Rhodes University, South Africa. All proton nuclear magnetic
resonance (1H NMR) spectra were recorded as CDCl3 or DMSO-d6
solutions (unless indicated otherwise) using tetramethyl silane
as an internal standard on a Bruker Ultrashield (400 MHz) spec-
trometer. Carbon-13 nuclear magnetic resonance (13C NMR)
spectra were recorded on the same instruments at 100 MHz
using tetramethylsilane as an internal standard. All chemical
shifts are reported in ppm.
Methylhydrazinecarbodithioate (6)
To an ice-cooled solution of KOH (22.41 g, 399.3 mmol) in
50 mL of H2O:isopropanol (1:1) was added hydrazine mono-
hydrate (19.40 mL, 399.2 mmol) followed by a drop-wise addition
of CS2 (24.10 mL, 399.9 mmol) while maintaining the tempera-
ture between 0–10 °C. After stirring for three hours, ice-cooled
CH3I (24.90 mL, 400.0 mmol) was added drop-wise and the reac-
tion mixture was left stirring for four hours. The resulting pre-
cipitate was filtered, washed several times with cold water and
recrystallized from dichloromethane to provide 6 as a white
crystalline solid in 90 % yield; mp 80–83 °C (Lit. 81–83 °C)22;
1H NMR (CD3OD, 400 MHz): Ç 2.52 (s, 3H, CH3);
13C NMR
(CD3OD, 100 MHz): Ç 194.5 (C=S), 17.2 (CH3). The spectroscopic
data were in agreement with the reported data.23
4-Prop-2-ynyloxybenzaldehyde (3)
A solution of 4-hydroxybenzaldehyde 1 (2.53 g, 20.5 mmol) in
acetone (20 mL) was treated with K2CO3 (4.21 g, 30.8 mmol). The
resulting reaction mixture was stirred under reflux for 30 min
followed by the addition of propargyl bromide (5.20 mL,
45.1 mmol of 80 wt.% in toluene). After stirring for 2 hours, the
reaction mixture was concentrated in vacuo. The residue was
then taken up in ethyl acetate, washed successively with water
and brine, and dried over Na2SO4. The crude product was puri-
fied by column chromatography (ethyl acetate/hexane, 2:8) to
give the title compound as a white solid in 92 % yield;
mp 75–78 °C (Lit. 79–80 °C)24; 1H NMR (CDCl3, 400 MHz): Ç 9.88
(s, 1H, CHO), 7.83 (d, 2H, J = 8.0 Hz, Ar), 7.07 (d, 2H, J = 8.0 Hz,
Ar), 4.76 (s, 2H, CH2), 2.54 (s, 1H, CÿCH);
13C NMR (CDCl3,
100 MHz): Ç 190.7 (C=O), 162.3, 131.8, 130.5, 115.1 (Ar), 77.5
(CÿCH), 76.3 (CÿCH), 55.9 (CH2OAr). The spectroscopic data
were in agreement with the reported data.20
1-[4-(1-Benzyl-1H-[1,2,3]triazol-4-ylmethoxy)-phenyl]-ethanone (4)
To a solution of 4-prop-2-ynyloxybenzaldehyde 3 (2.02 g,
12.5 mmol) in DMF:water (35 mL, 4:1) freshly prepared benzyl
azide (4.70 mL, 37.5 mmol), CuSO4
.5H2O (0.15 mmol, 37 mg,
dissolved in 0.50 mL of water) and sodium ascorbate (1.0 mmol,
0.2 g dissolved in 1 mL of water) were successively added at 60 °C
and the resulting reaction mixture was stirred at the same tem-
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Table 1 Synthesized thiosemicarbazone–triazole hybrids and their
yields.










Table 2 Summary of the pLDH assay of thiosemicarbazone-triazole 1a–i
at 10 µg/mL and of the standard chloroquine at 1 µg/mL incubated for
48 h.












perature for 3 h. After completion of the reaction, the reaction
mixture was transferred into a separatory funnel containing
brine (30 mL) and the aqueous layer was extracted with ethyl
acetate (3 × 40 mL). The combined organic layers were dried
over anhydrous Na2SO4 and the resulting crude product was pu-
rified by column chromatography (ethyl acetate/hexane, 4:6) to
give the title compound in 80 % yield as white crystals;
mp 100–103 °C; 1H NMR (CDCl3, 400 MHz): Ç 9.85 (s, 1H, CHO),
7.79 (d, 2H, J=8.4 Hz, Ar), 7.54 (s, 1H, H-triazole), 7.35–7.24 (m,
5H, Ar), 7.05 (d, 2H, J=8.4 Hz, Ar), 5.51 (s, 2H, CH2OAr), 5.23 (s,
2H, ArCH2N);
13C NMR (CDCl3, 100 MHz): Ç 190.8 (C=O), 163.1,
134.6, 132.0, 130.3, 129.2, 128.9, 128.1, 115.0 (Ar), 143.6
(N-C=CHN), 122.8 (N-C=CHN), 62.1 (ArCH2N), 54.3 (CH2OAr).
The spectroscopic data were in agreement with the reported
data.25
(Z)-methyl-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)
methoxy]benzylidene} hydrazine carbodithioate (7)
A solution of compound 4 (2.1 g, 6.8 mmol) in methanol
(20 mL) was treated with methylhydrazine carbodithioate 6
(0.81 g, 6.8 mmol). The reaction mixture was stirred overnight
under reflux. The hot solution was then poured into an ice-water
mixture and the precipitate formed was filtered and successively
washed with water and dichloromethane to provide the title
compound in 89 % yield as a yellow solid; mp 204–205 °C; IR
(neat, cm–1): 3130, 1600, 1304, 1220, 1059and 825; 1H NMR
(DMSO-d6, 400 MHz): Ç 13.20 (bs, 1H, NH), 8.28 (s, 1H,
H-triazole), 8.17 (s, 1H, ArCH=N), 7.64 (d, 2H, J = 8.4 Hz, Ar),
7.37–7.29 (m, 5H, Ar), 7.10 (d, 2H, J = 8.4 Hz, Ar), 5.59 (s, 2H,
CH2OAr), 5.18 (s, 2H, ArCH2N), 2.5 (s, 3H, CH3);
13C NMR
(DMSO-d6, 100 MHz): Ç 197.6 (C=S), 160.2, 136.0, 129.2, 128.9,
128.3, 128.0, 126.3, 115.4 (Ar), 146.3 (N-C=CHN), 142.7
(ArCH=N), 124.9 (N-C=CHN), 61.3 (ArCH2N), 53.0 (CH2OAr),
16.8 (CH3); Anal. Calcd. for C19H19N5OS2: C, 57.41; H, 4.82; N,
17.62; S, 16.13 %. Found: C, 54.38; H, 4.98; N, 16.97; S, 15.26 %.
General Procedure for the Synthesis of the Hybrid
Compounds
A solution of compound 7 (0.50 g, 1.3 mmol) in methanol
(10 mL) was treated with the alkyl amines (13.0 mmol) and the
resulting reaction mixture was stirred overnight under reflux.
The hot solution was then poured into an ice-water mixture and
the precipitate formed was filtered and recrystallized from a
mixture of dichloromethane and hexane to afford hybrids 1a–i:
(Z)-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzylidene}-
N-(2-hydroxyethyl)hydrazinecarbothioamide (1a): 62 % yield; white
solid; mp 206–208 °C; IR (neat, cm–1): 3355, 3151, 1605, 1280, 1224,
1049 and 827; 1H NMR (DMSO-d6, 400 MHz): Ç 11.41 (bs, 1H,
NH), 8.36 (bs, 1H, CH2NH), 8.30 (s, 1H, H-triazole), 7.99 (s, 1H,
ArCH=N), 7.71 (d, 2H, J = 8.4 Hz, Ar), 7.37–7.30 (m, 5H, Ar), 7.07
(d, 2H, J = 8.0 Hz, Ar), 5.6 (s, 2H, CH2OAr), 5.17 (s, 2H, ArCH2N),
4.81 (bs, 1H, OH), 3.61 (d, 2H, J = 5.2 Hz, HNCH2CH2OH), 3.55 (d,
2H, J = 4.8 Hz, HNCH2CH2OH); 13C NMR (DMSO-d6, 100 MHz):
Ç 176.9 (C=S), 159.4, 136.0, 128.8, 128.2, 128.0, 127.0, 114.9 (Ar),
142.7(N-C=CHN), 141.9 (ArCH=N), 124.8 (N-C=CHN), 61.2
(ArCH2N), 59.3 (HNCH2CH2OH), 52.9 (CH2OAr), 45.9
(HNCH2CH2OH). Anal. Calcd. for C20H22N6O2S: C, 58.52; H, 5.40;
N, 20.47; S, 7.81 %. Found C, 58.13; H, 5.76; N, 19.85; S, 8.10 %.
(Z)-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzylidene}-
N-(6-hydroxyhexyl)hydrazinecarbothioamide (1b): 66 % yield; white
solid; mp 146–148 °C; IR (neat, cm–1): 3407, 3364, 3145, 1604, 1297,
1218, 1052 and 824; 1H NMR (DMSO-d6, 400 MHz): Ç 11.24 (bs,
1H, NH), 8.45 (t, 1H, J = 5.4 Hz, CH2NH), 8.28 (s, 1H, H-triazole),
7.97 (s, 1H, ArCH=N), 7.72 (d, 2H, J = 8.4 Hz, Ar), 7.38–7.29 (m,
5H, Ar), 7.05 (d, 2H, J = 8.4 Hz, Ar), 5.59 (s, 2H, CH2OAr), 5.16 (s,
2H, ArCH2N), 4.50–4.35 (m, 1H,OH), 3.37 (d, 2H, J = 5.6 Hz,
HN(CH2)5CH2OH), 1.57–1.10 (m, 10H, 5 × CH2); 13C NMR
(DMSO-d6, 100 MHz): Ç 176.7 (C=S), 159.5, 136.1, 129.0, 128.9,
128.4, 128.1, 127.2, 115.0 (Ar), 142.9 (N-C=CHN), 141.9
(ArCH=N), 124.9 (N-C=CHN), 61.3 (ArCH2N), 60.8 (alkyl CH2),
53.0 (CH2OAr), 43.6, 32.6, 29.2, 26.4, 25.5 (5 × CH2); Anal. Calcd.
for C24H30N6OS: C, 61.78; H, 6.48; N, 18.01; S, 6.87 %. Found: C,
61.21; H, 6.76; N, 17.84; S, 6.61 %.
(Z)-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzylidene}-N-
pentylhydrazinecarbothioamide (1c): 80 % yield; white solid;
mp 147–149 °C; IR (neat, cm–1): 3303, 3170, 1604, 1298, 1223, 1050
and 824; 1H NMR (CDCl3, 400 MHz): Ç 9.71 (bs, 1H, NH), 7.79 (s,
1H, ArCH=N), 7.54 (s, 1H, H-triazole), 7.52 (s, 2H, Ar), 7.39–7.34
(m, 3H, Ar), 7.25 (d, 2H,J = 7.2 Hz, Ar), 6.96 (d, 2H, J = 8.4 Hz, Ar),
5.51 (s, 2H, CH2OAr), 5.19 (s, 2H, ArCH2N), 3.80–3.60 (m, 2H,
HNCH2(CH2)3CH3), 1.80–1.52 (m, 2H, HNCH2CH2(CH2)2CH3)
1.50–1.24 (m, 4H, HNCH2CH2(CH2)2CH3), 0.89 (s, 3H, CH3);
13C NMR (CDCl3, 100 MHz): Ç 177.0 (C=S), 160.0, 134.3, 129.1,
128.8, 128.1, 126.5, 115.1 (Ar), 144.0 (N-C=CHN), 142.1
(ArCH=N), 122.7 (N-C=CHN), 62.1 (ArCH2N), 54.3 (CH2OAr),
44.5, 29.0, 28.9, 22.3 (alkyl CH2), 14.0 (CH3); Anal. Calcd. for
C23H28N6OS: C, 63.28; H, 6.46; N, 19.25; S, 7.34 %. Found: C, 63.32;
H, 6.79; N, 18.82; S, 7.05 %.
(Z)-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzylidene}-N-
octylhydrazinecarbothioamide (1d): 85 % yield; white solid;
mp 145–147 °C; IR (neat, cm–1): 3330, 3149, 1605, 1296, 1231, 1054
and 831; 1H NMR (CDCl3, 400 MHz): Ç 9.62 (bs, 1H, NH), 7.78 (s,
1H, ArCH=N), 7.55 (s, 1H, H-triazole), 7.52 (s, 2H, Ar), 7.40–7.34
(m, 3H, Ar), 7.25 (d, 2H, J = 9.2 Hz, Ar), 6.96 (d, 2H, J = 8.4 Hz, Ar),
5.51 (s, 2H, CH2OAr), 5.19 (s, 2H,ArCH2N), 3.80–3.60 (m, 2H,
HNCH2(CH2)6CH3),1.75–1.56 (m, 2H, HNCH2CH2(CH2)5CH3),
1.50–1.12 (m, 10H, HNCH2CH2(CH2)5CH3), 0.92–0.3 (m, 3H, CH3);
13C NMR (CDCl3, 100 MHz): Ç 176.6 (C=S), 159.9, 134.1, 129.2,
128.9, 128.2, 126.5, 115.1 (Ar), 143.8 (N-C=CHN), 142.4
(ArCH=N), 122.9 (N-C=CHN), 61.9 (ArCH2N), 54.4 (CH2OAr),
53.4, 44.5, 31.7, 29.2, 29.1, 26.9, 22.6 (CH2), 14.1 (CH3); Anal. Calcd.
for C26H34N6OS: C, 65.24; H, 7.16; N, 17.56; S, 6.70 %. Found: C,
64.89; H, 7.84; N, 17.50; S, 6.49 %.
(Z)-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzylidene}-N-
isobutylhydrazinecarbothioamide (1e): 70 % yield; white solid;
mp 174–175 °C; IR (neat, cm–1): 3375, 3137, 1605, 1290, 1211, 1051
and 833; 1H NMR (CDCl3, 400 MHz): Ç 9.82 (bs, 1H, NH), 7.81 (s,
1H, ArCH=N), 7.53 (s, 1H,H-triazole), 7.52 (s, 2H, Ar), 7.34 (s, 3H,
Ar), 7.25 (d, 2H, J = 4.4 Hz, Ar), 6.96 (d, 2H, J = 8.0 Hz, Ar), 5.51 (s,
2H, CH2OAr), 5.19 (s, 2H, ArCH2N), 3.53 (s, 2H, HNCH2), 2.15–
1.87 (m, 1H, HNCH2CH(CH3)2), 1.20–0.85 (m, 6H, 2 × CH3);
13C NMR (CDCl3, 100 MHz): Ç 177.2 (C=S), 160.0, 134.3, 129.1,
128.8, 128.1, 126.5, 115.1 (Ar), 144.0 (N-C=CHN), 142.2
(ArCH=N), 122.7 (N-C=CHN), 62.1 (ArCH2N), 54.3 (CH2OAr),
51.7 (HNCH2), 28.3 (HNCH2CH(CH3)2), 20.3 (CH3); Anal. Calcd.
for C22H26N6OS: C, 62.53; H, 6.20; N, 19.89; S, 7.59 %. Found: C,
62.03; H, 6.70; N, 19.78; S, 7.27 %.
(Z)-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzylidene}-N-
(2-(dimethylamino)ethyl)hydrazinecarbothioamide (1f): 78 % yield;
white solid; mp 179–180 °C; IR (neat, cm–1): 3360, 3165, 1604,
1275, 1212, 1050 and 831; 1H NMR (DMSO-d6, 400 MHz): Ç 11.36
(bs, 1H, NH), 8.35 (bs, 1H, CH2NH), 8.28 (s, 1H, H-triazole), 7.98
(s, 1H, ArCH=N), 7.69 (d, 2H, J = 8.0 Hz, Ar), 7.34–7.31 (m, 5H,
Ar), 7.06 (d, 2H, J = 8.0 Hz, Ar), 5.59 (s, 2H, CH2OAr), 5.16 (s, 2H,
ArCH2N), 3.62 (d, 2H, J = 5.6 Hz, HNCH2CH2), 2.44 (s, 2H,
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HNCH2CH2), 2.17 (s, 6H, 2 × CH3); 13C NMR (DMSO-d6,
100 MHz): Ç 176.8 (C=S), 159.6, 136.1, 128.9, 128.4, 128.1, 127.2,
115.1 (Ar), 142.9 (N-C=CHN), 142.1(ArCH=N), 124.9
(N-C=CHN), 61.3 (ArCH2N), 53.0 (CH2OAr), 57.8 (HNCH2CH2),
45.4 (CH3), 41.42 (HNCH2CH2); Anal. Calcd. for C22H27N7OS: C,
60.39; H, 6.22; N, 22.41; S, 7.33 %. Found: C, 59.92; H, 6.57; N,
21.91; S, 7.12 %.
(Z)-N-benzyl-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl]methoxy}benzyl
idenehydrazinecarbothioamide (1g): 72 % yield; white solid;
mp 200–202 °C; IR (neat, cm–1): 3363, 3134, 1604, 1291, 1224, 1051
and 829; 1H NMR(DMSO-d6, 400 MHz): Ç 11.50 (bs, 1H, NH), 9.03
(t, 1H, J = 6.2 Hz, CH2NH), 8.28 (s, 1H, H-triazole), 8.03 (s, 1H,
ArCH=N), 7.75 (d, 2H, J = 8.8 Hz, Ar), 7.35–7.22 (m, 10H, Ar), 7.05
(d, 2H, J = 8.4 Hz, Ar), 5.6 (s, 2H, CH2OAr), 5.17 (s, 2H, ArCH2N),
4.83 (d, 2H, J = 6.0 Hz, HNCH2Ar); 13C NMR (DMSO-d6,
100 MHz): Ç 177.3 (C=S), 159.4, 139.6, 136.0, 128.9, 128.8, 128.2,
128.1, 128.0, 127.2, 127.1, 126.7, 114.9 (Ar), 142.8 (N-C=CHN),
142.1 ArCH=N), 124.8 (N-C=CHN), 61.2 (ArCH2N), 52.9
(CH2OAr), 46.5 (HNCH2Ar); Anal. Calcd. for C25H24N6OS: C,
65.77; H, 5.30; N, 18.40; S, 7.02. Found: C, 65.83; H, 5.82; N, 18.38;
S, 6.74 %.
(Z)-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]benzylidene}-N-
phenethylhydrazinecarbothioamide (1h): 74 % yield; white solid;
mp 165–167 °C; IR (neat, cm–1): 3298, 3149, 1602, 1298, 1223, 1049
and 825; 1H NMR (CDCl3, 400 MHz): Ç 9.69 (bs, 1H, NH), 7.74 (s,
1H, ArCH=N), 7.52 (s, 1H, H-triazole), 7.42 (d, 2H, J = 8.4 Hz,
Ar), 7.34–7.24 (m, 10H, Ar), 6.94 (d, 2H, J = 8.4 Hz, Ar), 5.52 (s, 2H,
CH2OAr), 5.20 (s, 2H, ArCH2N), 4.02–3.84 (m, 2H, HNCH2CH2Ar),
2.96 (t, 2H, J = 6.8 Hz, HNCH2CH2Ar); 13C NMR(CDCl3,
100 MHz): Ç 177.0 (C=S), 160.0, 138.6, 134.3, 129.1, 128.9, 128.8,
128.7, 128.1, 126.6, 126.5, 115.1 (Ar), 144.0 (N-C=CHN), 142.0
(ArCH=N), 122.7 (N-C=CHN), 62.1 (ArCH2N), 54.3 (CH2OAr),
45.3 (HNCH2CH2Ar), 35.3 (HNCH2CH2Ar); Anal. Calcd. for
C26H26N6OS: C, 66.36; H, 5.57; N, 17.86; S, 6.81 %. Found: C, 65.72;
H, 5.61; N, 17.73; S, 7.22 %.
(Z)-N-anilinyl-2-{4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methoxy]
benzylidene}-N-phenethylhydrazinecarbothioamide (1i): 64 % yield;
grey solid; mp 167–169 °C; IR (neat, cm–1): 3299, 3235, 3135, 3048,
1603, 1289, 1225, 1054, 822; 1H NMR: (DMSO-d6, 400 MHz):
Ç 10.13 (bs, 1H, NH), 8.26 (s, 1H, H-triazole), 7.80 (s, 1H,
ArCH=N), 7.56 (d, 2H, J = 8.4 Hz, Ar), 7.43–6.61 (m, 12H, Ar),
5.59 (s, 2H, CH2OAr), 5.14 (s, 2H, ArCH2N); 13C NMR: (DMSO-d6,
100 MHz): Ç 158.2, 136.6, 136.1, 129.3, 129.0, 128.9, 128.4, 128.1,
127.2, 118.6, 115.2, 112.0 (Ar), 145.7 (N-C=CHN), 143.1
(ArCH=N), 124.9 (N-C=CHN), 61.2 (ArCH2N), 53.0 (CH2OAr);
Anal. Calcd. for C24H23N7OS : C, 63.00; H, 5.07; N, 21.43; S, 7.01 %.
Found: C, 62.88; H, 5.17; N, 21.17; S, 6.96 %.
Antimalarial Assay
The in vitro antimalarial activity of the hybrids 1a–i against
the 3D7 strain of the malaria parasite, Plasmodium falciparum, is
measured by assessing parasite survival after drug exposure
using a parasite lactate dehydrogenase (pLDH) colorimetric
enzyme assay. Lactate dehydrogenase is an enzyme found in all
cells and catalyses the formation of pyruvate from lactate by
reducing the co-enzyme NAD + (nicotinamide adenine
dinucleotide) to NADH. In the pLDH assay, the NAD analogue
APAD (3-acetylpyridine adenine nucleotide) is reduced
to APADH and in turn a yellow NBT/PES (nitro blue tetra-
zolium + phenazine ethosulphate) reagent is converted to pur-
ple formazan crystals. The absorbance is read at 620 nm using a
multi-well spectrophotometer (Tecan Infinite F500). Formazan
formation is directly proportional to pLDH activity which in
turn is indicative of the number of parasites in the cultures
following drug exposure. Assay specificity is ensured by the
inability of human LDH, found in the host red blood cells, to
use APAD as a co-factor.
Compound inhibitory activity is determined by preparing test
samples in parasite culture medium in transparent 96-well flat
bottom plates (Greiner Bio-one) – 10 µM concentrations (n = 4
for each data point). Parasitized red blood cells are added to a
final concentration of 1 % haematocrit, 2 % parasitaemia and the
plates incubated for 48 hours before proceeding with the
pLDH assay. Percentage parasite survival in each well is calcu-
lated relative to control wells that receive no drug.
Crystal Structure Report
A colourless, plate-like specimen of C17H17N3O2, approximate
dimensions 0.05 mm × 0.20 mm × 0.25 mm, was used for the
X-ray crystallographic analysis. The X-ray intensity data were
measured as follows. A total of 2980 frames were collected. The
total exposure time was 8.28 hours. The frames were integrated
with the Bruker SAINT software package using a narrow-frame
algorithm. The integration of the data using an orthorhombic
unit cell yielded a total of 26836 reflections to a maximum è angle
of 65.49 (0.85 Å resolution), of which 2479 were independent
(average redundancy 10.825, completeness = 99.2 %, Rint =
3.52 %, Rsig = 1.77 %) and 2333 (94.11 %) were greater than 2ë(F
2).
The final cell constants of a = 11.2999(4) Å, b = 8.3445(3) Å, c =
30.7514(10) Å, volume = 2899.61(17) Å3, are based upon the re-
finement of the XYZ-centroids of 9837 reflections above 20 ë(I)
with 5.748 ° < 2è < 130.1 °. Data were corrected for absorption
effects using the multi-scan method (SADABS). The ratio of
minimum to maximum apparent transmission was 0.827. The
calculated minimum and maximum transmission coefficients
(based on crystal size) are 0.8397 and 0.9655. The structure was
solved and refined using the Bruker SHELXTL Software Package,
using the space group P b c a, with Z = 8 for the formula unit,
C17H17N3O2. The final anisotropic full-matrix least-squares
refinement on F2 with 199 variables converged at R1 = 4.08 %, for
the observed data and wR2 = 10.68 % for all data. The good-
ness-of-fit was 1.222. The largest peak in the final difference elec-
tron density synthesis was 0.139 e–/Å3 and the largest hole was
–0.675 e–/Å3 with an RMS deviation of 0.047 e–/Å3. On the basis of
the final model, the calculated density was 1.353 g/cm3 and
F(000), 1248 e–. Crystallographic data for the structure have been
deposited with the Cambridge Crystallographic Data Centre as
deposition No. CCDC-934893.
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